BA attenuated the decrease in the expression of ZO-1 and Occludin induced by LPS in Caco2 cells. by Luqiong Liu (11537092)

Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

Subjects:

Y-27632 collaborated with BA to attenuate the increase in the integrity and decrease in the permeability of epithelial barrier injury induced by LPS in Caco2 monolayers. by Luqiong Liu (11537092)

“…The values are expressed as the means ± SDs and were analyzed according to the variance of the factorial design. **, *** and ****denote <i>p</i> < 0.01, < 0.001 and < 0.0001, respectively; ns  =  not significant.…”

Y-27632 synergized with BA to alleviate the decrease in the expression of and abnormal localization of ZO-1 and Occludin in LPS-induced Caco2 cells. by Luqiong Liu (11537092)

Clinical course of patient no. by Kazuyoshi Ohkawa (836847)

Subjects:

Summary of clinical efficacy of relevant PTSD treatments. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

Mean Values and Standard Deviations (Mean [±SD]) of Clinical Parameters: periodontal probing depth (PPD), clinical attachment level (CAL), bleeding on probing (BOP), and plaque ind... by Iva Milinkovic (22331710)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

Subjects:

Post-treatment CAPS score changes from clinical trials with off-label PTSD medications. by Filip Stanicic (17808254)

Subjects:

Clinical features and cancer treatment in patients with breast cancer receiving letrozole and anastrozole. by Kazuyoshi Ohkawa (836847)

Subjects:

Variants assigned Clinvar pathogenic clinical significance. by Anastasiia Buianova (19871022)

Subjects:

Summary of the effect of MPDD on SDLP across all participants, and also participants categorized by driving styles (“NS” (no significant), “+” (significant increase), and “-” (sign... by Mobina Faqani (22783963)

Summary of the effect of MPDD on ART and TIBL across all participants, and also participants categorized by driving styles (“NS” (no significant), “+” (significant increase), and “... by Mobina Faqani (22783963)

Related inflammation evaluation indexes before and after operation (mean±standard deviation). by Na Wang (193263)

Subjects:

Baseline data of each group (mean±standard deviation)/n (%)/(M(IQR)). by Na Wang (193263)

Subjects:

Relevant follow-up evaluation indicators after operation (mean±standard deviation)/n (%). by Na Wang (193263)

Subjects:

Distribution of significant SNVs across disease severity. by Varsha Ravi (12267659)

Subjects: